TheScreener - Arena Pharmaceuticals Inc. (ARNA) ARENA PHARMA sees a downgrade to Slightly Negative on account of less fundamental stars

Report

TheScreener

EUR 13.98 For Business Accounts Only

ARENA PHARMA sees a downgrade to Slightly Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of ARENA PHARMA (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered moderately risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Slightly Negative. As of the analysis date October 19, 2021, the closing price was USD 60.94 and its target price was estimated at USD 46.84.

20/10/2021 6 EN

Underlying

Arena Pharmaceuticals Inc.

Arena Pharmaceuticals is a biopharmaceutical company focused on delivering medicines with pharmacology and pharmacokinetics to patients globally. The company's clinical programs include: etrasimod (APD334), which is being evaluated in ulcerative colitis, a program for Crohn's disease, as well as a program for atopic dermatitis; olorinab (APD371), which is is being evaluated for a range of visceral pain conditions associated with gastrointestinal diseases and for treatment of abdominal pain associated with irritable bowel syndrome; and APD418, which is being evaluated in a trial for acute heart failure.

See profile

US0400476075 NASDAQ Stock Market United States

Provider

TheScreener

Empowering Investors

theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.

Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.

See profile

Other Reports on these Companies

Vermilion Research

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

EUR 46.59

June 28, 2021 June 28, 2021 21 EN

BusinessWire

Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX

PARK CITY, Utah--(BUSINESS WIRE)-- (Nasdaq: ARNA) today announced additional data at a late-breaking session at the . Etrasimod, a novel investigational drug candidate to treat moderate-to-severe atopic dermatitis (AD), demonstrated statistical significance in both clinician and patient reported outcomes in the etrasimod 2 mg treatment group of Arena’s ADVISE Phase 2b clinical trial. Etrasimod is a highly selective, once-daily, oral sphingosine 1-phosphate (S1P) receptor modulator. Topline results from the ADVISE Phase 2b clinical trial were announced in November 2020. Today’s results were pre...

April 23, 2021 April 23, 2021 1 EN

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

AC ENERGY CORP (PH), a company active in the Alternative Electricity industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 4 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date April 8, 2022, the closing price was PHP 8.54 and its expected value was estimated at PHP 8.53.

Free Trial

April 9, 2022 April 9, 2022 1 EN

With a more favourable environment, VUKILE PROPERTY improves to Positive

VUKILE PROPERTY (ZA), a company active in the Real Estate Holding & Development industry, is favoured by a more supportive environment. The independent financial analyst theScreener has confirmed the fundamental rating of the title, which shows 4 out of 4 stars, as well as its unchanged, defensive market behaviour. The title leverages a more favourable environment and raises its general evaluation to Positive. As of the analysis date April 5, 2022, the closing price was ZAR 13.72 and its potential was estimated at ZAR 15.16.

Free Trial

April 6, 2022 April 6, 2022 1 EN

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

The independent financial analyst theScreener just requalified the general evaluation of ROYAL BAFOKENG PLATINUM (ZA), active in the Platinum & Precious Metals industry. As regards its fundamental valuation, the title still shows 0 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date April 5, 2022, the closing price was ZAR 159.78 and its target price was estimated at ZAR 127.50.

Free Trial

April 6, 2022 April 6, 2022 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ARENA PHARMA sees a downgrade to Slightly Negative on account of less fundamental stars

Empowering Investors

Vital Signs: Actionable charts

Arena Pharmaceuticals Presents Clinician and Patient Reported Outcomes Data from Phase 2b ADVISE Trial Evaluating Etrasimod in Adult Atopic Dermatitis During a Late-Breaking Session at American Academy of Dermatology VMX

AC ENERGY CORP increases its risk exposure and slightly lowers to Neutral

With a more favourable environment, VUKILE PROPERTY improves to Positive

An unfavourable environment weighs on ROYAL BAFOKENG PLATINUM, which sees a downgrade to Slightly Negative

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe